Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 41; pp. 7515 - 7516
Autores principales: Harker-Murray, Paul David, Cole, Peter D., Hoppe, Bradford S., Hodgson, David C., Beishuizen, Auke, Garnier, Nathalie, Buffardi, Salvatore, Mascarin, Maurizio, Lissat, Andrej, Akyol, Alev, Crowe, Russell, Li, Ju, Drachtman, Richard A., Kelly, Kara M, Leblanc, Thierry, Daw, Stephen
Formato: Journal Article
Publicado: American Society of Clinical Oncology 2023 Supplement 16
Acceso en línea:Ver este registro en EBSCOhost